Results 11 to 20 of about 30 (29)
Some of the next articles are maybe not open access.

Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia

Lancet, The, 2020
Denis Y Logunov   +2 more
exaly  

Adeno-associated virus vector as a platform for gene therapy delivery

Nature Reviews Drug Discovery, 2019
Dan Wang, Phillip W L Tai, Guangping Gao
exaly  

Controlling vector-borne diseases by releasing modified mosquitoes

Nature Reviews Microbiology, 2018
Heather A Flores, Scott L O'neill
exaly  

Drivers, dynamics, and control of emerging vector-borne zoonotic diseases

Lancet, The, 2012
A Marm Kilpatrick
exaly  

Effectiveness of reactive focal mass drug administration and reactive focal vector control to reduce malaria transmission in the low malaria-endemic setting of Namibia: a cluster-randomised controlled, open-label, two-by-two factorial design trial

Lancet, The, 2020
Michelle S Hsiang   +2 more
exaly  

Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial

Lancet, The, 2014
Philip C Buttery   +2 more
exaly  

Ultrafast vector imaging of plasmonic skyrmion dynamics with deep subwavelength resolution

Science, 2020
Timothy Davis   +2 more
exaly  

Human Induced Pluripotent Stem Cells Free of Vector and Transgene Sequences

Science, 2009
Kejin Hu, Shulan Tian, Igor I Slukvin
exaly  

Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial

Lancet, The, 2017
Qiang Guo, Zhe Zhang, Wei Chen
exaly  

Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector

Lancet, The, 2004
Kimberly C Gilmour   +2 more
exaly  
previous   1  2  3  

Home - About - Disclaimer - Privacy